Alvotech Reels In Abdi Ibrahim For Access To Turkey
In a move to take its pipeline of biosimilar monoclonal antibodies global, Alvotech has struck a deal with Abdi Ibrahim that will give it localization advantages in Turkey.
You may also be interested in...
Alvotech has struck an investment deal worth $45m with Yas Holding that will give Yas a 2.5% stake in the business, as well as rights to sell three Alvotech biosimilars in the MENA region.
Alvotech and Fuji Pharma have extended their alliance to cover exclusive development and supply of biosimilar ustekinumab in Japan.
Alvotech will further develop its biosimilar assets through a US$300 million financing deal that will also enable the firm to “fuel continued growth” and be used for refinancing existing debt.